Mezzion Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Mezzion Pharma is a South Korean drug-development company focused on creating new medicines for conditions such as single-ventricle heart disease, pulmonary arterial hypertension, erectile dysfunction, enlarged prostate, portal hypertension, and autosomal dominant polycystic kidney disease.
Its pipeline targets patients and healthcare systems globally, with the US Food and Drug Administration as a key regulatory gatekeeper. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business centres entirely on clinical-stage drug development rather than commercialised product sales.
Summary is AI-generated and may contain errors · figures from DART filings
Mezzion Pharma in five facts
What does Mezzion Pharma do?
Mezzion Pharma is a South Korean drug-development company focused on creating new medicines for conditions such as single-ventricle heart disease, pulmonary arterial hypertension, erectile dysfunction, enlarged prostate, portal hypertension, and autosomal dominant polycystic kidney disease.
Where is Mezzion Pharma listed and in which sector?
Mezzion Pharma (Korean name: 메지온) trades under KRX code 140410 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Mezzion Pharma?
Its market capitalisation was US$1.4B on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Mezzion Pharma's latest annual revenue and operating profit?
For fiscal year 2025, Mezzion Pharma reported revenue of US$6M, an operating loss of US$12.7M and a net loss of US$26.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 8.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 20
- Report on large shareholdings (5% rule) (standard)Oct 8
- Report on large shareholdings (5% rule) (standard)Oct 2
- Material event report (decision to redeem own convertible bonds early)Capital raise · May 22
- Material event report (decision to redeem own convertible bonds early)Capital raise · May 22
- Material event report (convertible bonds)
Mezzion Pharma disclosed convertible bonds to raise US$24.8M, about 1.7% of its market value.
Capital raise · Apr 30 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Mezzion Pharma reported consolidated results for FY2025: revenue of US$5.38M (−8.1% year on year), an operating loss of US$11.4M and a net loss of US$23.8M.
Earnings · Mar 13